Application of 4-carbamoyl-1-.beta.-D-ribofuranosyl imidazolium-

Details Application of 4-carbamoyl-1-.beta.-D-ribofuranosyl imidazolium- Application of 4-carbamoyl-1-.beta.-D-ribofuranosyl imidazolium-

1994-07-28

1995-12-05

Robinson, Douglas W.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

536 288, 514903, A61K 3170

Patent

active

054729475

ABSTRACT:
A composition for the treatment or prevention of multiple sclerosis is disclosed. It comprises mizoribine (4-carbamoyl-1-.beta.-D-ribofuranosyl imidazolium-5-olate) as the effective component. It is a safe drug, exhibiting a minimal degree of side-effects, and thus can be administered over a long period of time. Administration of the drug, usually 1-20 mg/kg (body weight) per day for adults, improves the functional disturbances of multiple sclerosis.

REFERENCES:
patent: 3888843 (1975-06-01), Mizuno et al.
patent: 4728729 (1988-03-01), Tarumi et al.
"Toyo Jozo Expanding Indicators of Existing Immunosuppressant and Developing New Immunoregulator," The Chemical Daily(Japan), Feb. 26, 1991, p. 9.
Mizuno et al., "Studies on Bredinin. I. Isolation, Characterization and Biological Properties," The Journal of Antibiotics, 27(10), 775-782 (1974).
Hayashi et al., "Studies on Bredinin. III. Chemical Synthesis of Bredinin (A Novel Imidazole Nucleoside)," Chem. Pharm. Bull., 23(1), 245-246 (1975).
"Symposium: [Review of the Status of Immunomodulating Therapies in Multiple Sclerosis]," Neurology, 38(Suppl. 2), pp. 4-89 (Jul., 1988).
Szobor et al., "Treatment of Multiple Sclerosis," Ther. Hung., 37(2), 67-82 (1989).
Budavari et al. (eds.), The Merck Index, 11th Ed., Merck & Co., Rahway, N.J., 1989, pp. 144, 431 and 980.
Berkow et al. eds. The Merck Manual of Diagnosis and Therapy, Merck Research Laboratories, Rahway, N.J., 1992, pp. 1487-1490.
Yudkin et al., "Overview of Azathioprine Treatment in Multiple Sclerosis," The Lancet, 338, 1051-1055 (1991).
R. A. C. Hughes et al., "Double-masked Trial of Azathioprine in Multiple Sclerosis," The Lancet, 1988, 179-183.
Milanese et al., "Double Blind Controlled Randomized Study on Azathioprine Efficacy in Multiple Sclerosis. Preliminary Results," Ital. J. Neurology, 9, 53-57 (1988).
Ellison et al., "A Placebo-controlled, Randomized, Double-masked, Variable Dosage, Clinical Trial of Azathioprine With and Without Methylprednisolone in Multiple Sclerosis," Neurology, 39, 1018-1026 (1989).

Affiliated with

Also associated with

Rating

Application of 4-carbamoyl-1-.beta.-D-ribofuranosyl imidazolium- does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Application of 4-carbamoyl-1-.beta.-D-ribofuranosyl imidazolium-, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Application of 4-carbamoyl-1-.beta.-D-ribofuranosyl imidazolium- will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1374204